Intech Investment Management LLC Invests $136,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Intech Investment Management LLC acquired a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,968 shares of the company’s stock, valued at approximately $136,000.

A number of other hedge funds have also recently added to or reduced their stakes in EYPT. China Universal Asset Management Co. Ltd. boosted its holdings in EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after buying an additional 4,172 shares in the last quarter. Greenwich Wealth Management LLC boosted its holdings in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after buying an additional 900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after buying an additional 7,953 shares in the last quarter. Cyndeo Wealth Partners LLC purchased a new stake in EyePoint Pharmaceuticals during the third quarter worth $100,000. Finally, Arizona State Retirement System boosted its holdings in EyePoint Pharmaceuticals by 9.7% during the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $115,000 after buying an additional 1,171 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EYPT shares. Robert W. Baird lowered their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Chardan Capital increased their price target on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Jefferies Financial Group assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday. Finally, Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective on the stock. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Stock Up 6.7 %

Shares of NASDAQ EYPT opened at $8.71 on Friday. The firm has a 50-day simple moving average of $9.81 and a 200-day simple moving average of $9.30. The stock has a market capitalization of $594.47 million, a price-to-earnings ratio of -4.36 and a beta of 1.45. EyePoint Pharmaceuticals, Inc. has a 52 week low of $7.40 and a 52 week high of $30.99.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.